The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Led by CEO Kevin Hochman—who formerly oversaw similar revivals at Old Spice and KFC—Chili’s has transformed from a ’90s relic ...